About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

COMPLETEDPhase 3NCT00282984

Efficacy and Safety of Varenicline in Smokers With Cardiovascular Disease Who Wish to Quit Smoking

The primary purpose of this study is to determine whether or not varenicline will help people with cardiovascular disease quit smoking and to confirm it is safe in these patients.

Lead sponsor: Pfizer•3 U.S. locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Clareo turns complex medical information into clear understanding you can use.

Bring this clarity to your next appointment.

Keep all your medical notes and next steps in one place.

Sponsors

Lead Sponsor

Pfizer

Age

35 - 75 years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•Participants must have stable, documented cardiovascular disease (including at least one of the following diagnosed \> 2 months prior to the Screening visit - angina, myocardial infarction (MI), revascularization, transient ischemic attack (TIA), and peripheral vascular disease (PVD).
•Participants that smoke \> 10 cigarettes / day.

Exclusion Criteria

•Participants with unstable cardiovascular disease
•Cardiovascular events in the past 2 months
•Moderate or severe chronic obstructive pulmonary disease (COPD)

Related studies

RECRUITINGPhase 4

Using Multiphase Optimization Strategy (MOST) to Optimize a Cost-effective, Sustainable and Scalable Smoking Cessation Package for Smokers in HIV Clinical Care

NCT06598397 · Human Immunodeficiency Virus (HIV), Smoking Cessation

Oklahoma Study of Native American Pain Risk IV: Smoking Cessation and Pain

NCT07080788 · Smoking Cessation Intervention, Pain, and more

Effects of Smoking on Network Connectivity in Patients With Schizophrenia Symptoms in Scz Patients

NCT07441928 · Smoking Cessation, Schizophenia Disorder

Personalized Tobacco Treatment in Primary Care (MOTIVATE)

NCT05846841 · Physician's Role, Smoking Cessation, and more

Mindfulness-based Ecological Momentary Intervention for Smoking Cessation Among Cancer Survivors

NCT07210567 · Smoking Cessation

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: April 5, 2017Terms

Trial snapshot

StatusCOMPLETED

PhasePHASE3

Enrollment714

Start dateFeb 2006

Last updatedApr 5, 2017

Condition

Smoking Cessation

Locations shown

Pfizer Investigational Site

Hartford, Connecticut

Pfizer Investigational Site

Boston, Massachusetts

Pfizer Investigational Site

Madison, Wisconsin

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: April 5, 2017Data synced to Clareo: May 3, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions